The ever increasing pace of aesthetic medical innovation recently saw another exciting new product added to the clinical ‘toolkit’. Reducing a double-chin, or fat under the jawline, without surgery or liposuction has been difficult until now. Last week the FDA (U.S. Food and Drug Administration) approved a new injection therapy called Kybella (Kythera Biopharmaceuticals, Inc.) which was approved for the reduction of moderate to severe fat deposits under the chin. The active ingredient in Kybella, deoxycholic acid, dissolves fat, allowing dermatologists and aesthetic surgeons to resculpt the chin area without surgery. Dr. Heidi Waldorf, an internationally respected expert in the field of noninvasive skin rejuvenation and dermatology, including the use of soft tissue augmentation, botulinum toxins, topical cosmeceuticals, lasers, and other devices, was a lead clinical investigator on Kybella leading to its approval.
Dr. Waldorf is also Director of Laser and Cosmetic Dermatology at The Mount Sinai Hospital and Associate Clinical Professor at the Icahn School of Medicine of Mount Sinai University and sees patients in Nanuet, New York, at Waldorf Dermatology & Laser Associates, and at Mount Sinai Hospital. Being involved as a lead clinical investigator with new products that may enable better patient results, and possibly even change and influence how certain procedures are performed, is an exciting part of any doctor’s career. Listen to the Aesthetic Insider radio for a special glimpse into how Dr. Waldorf combines running a successful practice with important clinical investigation. To learn more call 845-623-7077 or 212-241-0472.